RC148
Phase 3Small molecule
RC148 is one of 143 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
6
Indications
6
Total Trials
6
Active Trials
142
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1RC148
RRemeGen Co., Ltd.
Phase 3
Adenocard
AstellasPreclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Tianeptine
PfizerPreclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Sertraline ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Tc99m Sestamibi
MM.D. Anderson Cancer Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer1 trial
Locally Advanced Unresectable or Metastatic Solid Tumors1 trial
Locally Advanced or Metastatic NSCLC1 trial
Malignant Solid Tumors1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RC148. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRemeGen Co., Ltd.